Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fuji
McKesson
Healthtrust
Argus Health
US Department of Justice

Generated: September 24, 2019

DrugPatentWatch Database Preview

Patent: 8,808,689

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,808,689
Title:Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
Abstract: To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes.
Inventor(s): Levetan; Claresa (Bryn Mawr, PA)
Assignee: Perle Bioscience, Inc. (Atlanta, GA)
Application Number:13/768,472
Patent Claims:see list of patent claims

Details for Patent 8,808,689

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Try a Free Trial Perle Bioscience, Inc. (Atlanta, GA) 2032-09-27 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Perle Bioscience, Inc. (Atlanta, GA) 2032-09-27 RX search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Try a Free Trial Perle Bioscience, Inc. (Atlanta, GA) 2032-09-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
McKesson
Colorcon
US Department of Justice
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.